OT Staff Reports

The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected.

NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470

A team of investigators from Pohang University of Science and Technology has found that conjunctival goblet cell examination is important for the precise diagnosis and effective treatment of ocular surface diseases; however, CGC examination has not been possible until now due to lack of non-invasive devices.

According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.

The data support the ongoing development of KPI-012, a novel investigational secretome therapy, to address the complex wound healing process in persistent corneal epithelial defect (PCED).

Top-line results are expected during second quarter for the therapeutic to treat patients with dry eye disease.

The company’s Systane iLux2 Meibomian Gland Dysfunction Thermal Pulsation System is a handheld device that allows patients to see the need for treatment and visualize their procedure.

According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.

According to the company, the modifier gene therapy candidate is for the treatment of retinitis pigmentosa resulting from mutations in the nuclear receptor subfamily 2 group E member 3 and Rhodopsin genes.

The International Agency for the Prevention of Blindness (IAPB) recently announced an expansion of their ‘Focus on Glaucoma’ and ‘Focus on Diabetes’ series with their new ‘Focus on Child Eye Health’ series in partnership with CooperVision.

The company announced the expansion of its commercial rollout of its MIGS implant to the UK

Investigators at the International Center for Materials Nanoarchitectonics have developed the first-ever artificial retinal device that increases the edge contrast between lighter and darker areas of an image, using ionic migration and interaction within solid.

Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DME patients.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

A separate analysis will be presented at the American Academy of Neurology 2022 Annual Meeting, showing that UPLIZNA reduced pan associated with NMOSD over 3 years.

Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation.

The American College of Medical Genetics and Genomics Foundation for Genetic and Genomic Medicine grants its Next Generation Fellowship Awards to promising early-career professionals in a range of medical genetics and genomics specialties. The awards were presented at the 2022 ACMG Clinical Genetics Meeting.

The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.

The country’s Ministry of Health has issued infringement notices to two ophthalmologist for seeing patients while unvaccinated.

The MIRA-3 Phase 3 FDA Registration trial for Nyxol met its primary endpoint with 58% of treated subjects returning to baseline pupil diameter at 90 minutes compared to 6% of placebo subjects.

The company’s iCare HOME2 self-tonometer allows patients to collect real-world IOP data at any time.

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.

The EVO/EVO+ Visian Implantable Collamer Lens provides visual freedom independent of contact lenses and glasses.

The San Francisco-based company also announces that Raj K. Maturi, MD, is the first PI in the network.

Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.

The company notes that its clinical trial of the light delivery system meets the primary efficacy endpoint, and can offer hope to patients with dry AMD who are experiencing vision loss and currently have limited treatment options.

The company has dosed the first patients in a Phase 3 trial evaluating the safety and efficacy of Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

Investigators find that hybrid cells could be a potential therapeutic strategy to treat retinal damage and visual impairment.